Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

MedMira Inc (MMIRF)

OTC Markets
Currency in USD
Disclaimer
0.06
0.00(0.00%)
Closed

MMIRF Comments

Any news about this ?
linked to J & J and Fauci this should take off
this will be $2.00 by spring
MIR great biotechnology company with great marketable products is not lifting up. The current COVID environment is so alarming and should be the perfect time to make an upward move. What's holding them back is a surprise to me ??
https://stockhouse.com/companies/bullboard?symbol=v.mir&postid=32024822
earnings were are they June 16 ?
techical analysis indicates about a 0.70 price target or more for tomorrow if this keeps trending upward. looks like we're in phase 2 of the uptrend phase 3 might be huge. look out for it!
looking good today. we gonna pump it up another 0.10+ tomorrow?
"Medmira had to address the cash-flow deficit and, at the time, considered available means to raise the necessary funding and cover the operational deficit. Given our recent major sale agreement, MedMira is now able to secure the required finances through sales. Such actions are, most certainly, favorable to our shareholders and stakeholders." https://twitter.com/medmira/status/1268236578687791110/photo/1
BTFD
this is a good buy!
MedMira Announces Exclusive Distribution Partnership with Webb Diagnostic Technologies and Initial Order for REVEALCOVID-19™ Total Antibody Test in the U.S.[5/27/20] 13:00:10
https://www.wallstreet-online.de/nachricht/12553078-medmira-naechstem-paukenschlag-europaeischer-ce-zulassung-medmira-wichtige-europaeische-ce-zulassung-corona-schnelltest-aufnahme-deutsche-dimdi-aktie-massiv-riesenumsaetzen
I expect a production of around 10 million rapid tests a year that MedMira can handle together with third-party manufacturers. This means the company has net sales of approximately $ 250 million a year. With a profit margin of 70% for taxes, around USD 175 million remains. If we discount a safety margin of 40% here, we are still rounded at USD 100 million. A price-earnings ratio of 15 is very likely for such a company, which brings us to a valuation of $ 1.5 billion ($ 15 x $ 100 million). At the current USD-CAD exchange rate, this results in a valuation of around CAD 2.1 billion, which for around 659 million shares results in around CAD 3.20 per share. I know for you as a reader these are castles in the air, fantasy calculations etc. However, I always think about what can go where and what a calculated value results under the prevailing market and competitive conditions. Important: these are my own thoughts and number games. Everyone has to know what he is doing!
it will reach $1 by tomorrow. News comes out with FDA approval will pop up to $3 in two weeks.
pop until earnings. then drop like a rock
https://medmira.com/doks/pdf/PR_SARS-CoV-2__EU.docx.pdf
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.